"Amgen's Unique Approach to Tapping into the Growing Weight Loss Drug Market"

Amgen is developing an injectable weight loss drug called MariTide, which takes a different approach from existing treatments by blocking a gut hormone receptor called GIP. Early-stage trial data suggests that MariTide may help patients maintain weight loss even after stopping the drug, and the drug can be taken once a month or less frequently. Amgen's ongoing phase two trial will provide more clarity on the drug's effectiveness and tolerability, with initial results expected later this year.